The study could show a better clinical outcome of cervical cancer patients with unmethylated CDH1/13 compared to patients with the methylated genes (median disease-free survival for CDH1/13 unmethylated: 4.3 years, methylated: 1.2 years). This evidence concerns the gene CDH1 and cervical carcinoma.